When discussing this year's hottest terms in the pharmaceutical industry, bispecific antibodies, ADCs, and nucleic acid delivery definitely rank high. WCLC brought explosive data on bispecific ADCs, with everyone discussing how to execute "combination punches" more precisely. Coincidentally, this track perfectly aligns with BioCity's recent series of partnership announcements: exploring antibody-conjugated LNP nucleic acid delivery with Merck, signing an antibody licensing agreement with Tubulis for ADC development, and IDEAYA's bispecific ADC (IDE034) planning Q4 IND filing. Three consecutive moves with excellent timing.
**A Platform Biotech That "Stocks the Shelves"**
BioCity's most distinctive label is transforming the complex molecular discovery process into "shelf-style" selection:
"Thousand Mice, Ten Thousand Antibodies": Using RenMice® fully human antibody mice, targeting thousands of potential druggable targets to pre-generate a "massive candidate antibody library."
Advantage: Partners don't need to start from scratch with lengthy groundwork; they can directly select molecules and conduct validation, compressing time costs from years to 12-18 months while increasing project certainty. In short: while others are still "sharpening their tools," BioCity has already arranged the "tools" with labels attached.
**Why Are "Dual Business Lines" So Critical?**
BioCity divides its main engine into two parts:
Animal Model Business: Target-humanized mice, disease models, in vivo efficacy studies; providing stable cash flow and standardization capabilities.
Antibody Platform Business: RenMab®/RenLite®/RenNano® and other RenMice platforms continuously "produce antibodies," then deliver molecules globally through licensing, transfers, and joint development. These function like left and right hands: the left hand expands validation tools more broadly, while the right hand strengthens molecular supply. More collaboration partners create stronger positive feedback loops.
**BioCity's Latest Developments**
Antibody × Nucleic Acid Delivery: Partnering with Merck on LNP Precise Nucleic Acid Drug Delivery The bottleneck in nucleic acid drugs lies in delivery; antibody-conjugated LNPs could make "transport vehicles" better at navigation. BioCity supplies fully human antibodies while Merck evaluates feasibility—combining molecular sources with delivery technology maximizes potential: mRNA, siRNA... could all benefit. The agreement includes exclusive options + milestones + royalties, indicating deep collaboration potential.
ADC: Tubulis Acquires a "Sharp Blade" Tubulis selected a fully human antibody from the RenMice® platform to combine with their proprietary linkers and payloads for next-generation ADC development. BioCity receives upfront payments + milestones + sales royalties, exemplifying the typical "platform output—external enablement—shared results" pathway.
Bispecific ADC: IDEAYA's IDE034 New Progress IDE034, derived from the RenLite® shared light chain platform, can simultaneously target B7-H3 and PTK7 tumor-associated targets with low mispairing risk and CMC-friendly properties, as convenient as developing monoclonal antibodies. Preclinical studies show synergy when combined with DDR small molecules, with IND filing expected in Q4 2025, targeting multiple solid tumors.
**Riding the "BD Era" Tailwind**
Global pharmaceutical companies face patent cliffs and urgently need new pipelines; China's innovative drug efficiency and cost advantages are evident, creating supply-demand alignment that naturally drives BD transactions. BioCity's strategy perfectly captures this trend:
Rather than pursuing comprehensive in-house R&D, they focus on perfecting "molecular discovery + validation tools";
Open to the entire industry, allowing single molecules to be tested across different companies and indications, naturally increasing success rates;
Converting value into long-term cash flow through upfront payments + milestones + royalties. Simply put: they serve as an "accelerator," not a "solo fighter."
As the industry shifts from "single-target competition" to "multi-target + delivery system" three-dimensional warfare, whoever can more rapidly provide reliable molecules and validation tools becomes more like "infrastructure." Currently, BioCity's "dual business lines + thousand mice, ten thousand antibodies" approach has transformed this into "reproducible engineering."